is glp 1 semaglutide or tirzepatide vs for Weight Loss: Which Better? π₯ Your Guide to the
Description
Especially around regenerative models, muscle signaling, and metabolic pathways tied to GLPs
Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)
Will any of the 50+ clinical-stage assets currently in development meet these unmet needs?
Are employers ready for that trend to continue
While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in people with diabetes.
There is an ever-growing list of established indications for GLP-1 based medications
